DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 7,163,684
|Title:||Method of increasing bone toughness and stiffness and reducing fractures|
|Abstract:||The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracture, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.|
|Inventor(s):||Gaich; Gregory A. (Indianapolis, IN), Dere; Willard H. (Westlake Village Ventura, CA), Hock; Janet M. (Indianapolis, IN)|
|Assignee:||Eli Lilly and Company (Indianapolis, IN)|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for patent 7,163,684|
|Patent Claims:||1. A method for treating osteoporosis in a post-menopausal woman at high risk for fracture, comprising administering to said woman human parathyroid hormone (1 34), in a daily dose of
20 ug, without concurrent administration of an antiresorptive agent other than supplemental vitamin D or supplemental calcium, said treatment for increasing bone mineral density and reducing the risk of vertebral and non-vertebral bone fracture.
2. The method of claim 1 wherein said woman has at least one prior fragility fracture.
3. The method of claim 1 wherein the osteoporosis is selected from advanced-stage osteoporosis, hypogonadal osteoporosis, spinal osteoporosis, and steroid-induced osteoporosis.
4. The method of claim 3 wherein the osteoporosis is advanced-stage osteoporosis.
5. The method of claim 3 wherein the osteoporosis is spinal osteoporosis.
6. The method of claim 3 wherein the osteoporosis is steroid-induced osteoporosis.
7. The method of claim 1 wherein concurrent administration of supplemental vitamin D and supplemental calcium is excluded.
8. The method of claim 1 wherein supplemental vitamin D is concurrently administered.
9. The method of claim 1 wherein supplemental calcium is concurrently administered.
10. The method of claim 1 wherein supplemental vitamin D and supplemental calcium are concurrently administered.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Nps Pharms Inc||NATPARA||parathyroid hormone||INJECTABLE;INJECTION||125511||001||2015-01-23||Start Trial||Eli Lilly and Company (Indianapolis, IN)||2018-08-19||RX||Orphan||search|
|Nps Pharms Inc||NATPARA||parathyroid hormone||INJECTABLE;INJECTION||125511||002||2015-01-23||Start Trial||Eli Lilly and Company (Indianapolis, IN)||2018-08-19||RX||Orphan||search|
|Nps Pharms Inc||NATPARA||parathyroid hormone||INJECTABLE;INJECTION||125511||003||2015-01-23||Start Trial||Eli Lilly and Company (Indianapolis, IN)||2018-08-19||RX||Orphan||search|
|Nps Pharms Inc||NATPARA||parathyroid hormone||INJECTABLE;INJECTION||125511||004||2015-01-23||Start Trial||Eli Lilly and Company (Indianapolis, IN)||2018-08-19||RX||Orphan||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|South Africa||200004993||Start Trial|
|World Intellectual Property Organization (WIPO)||0010596||Start Trial|
|United States of America||2004033950||Start Trial|
|United States of America||2005197294||Start Trial|
|United States of America||2006094642||Start Trial|
|United States of America||2007161567||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.